Author:
Stucki A.,Cottagnoud M.,Acosta F.,Egerman U.,Läuffer J.,Cottagnoud P.
Abstract
ABSTRACTCeftobiprole medocaril, a new cephalosporin, is highly active against a broad spectrum of Gram-positive and Gram-negative clinical pathogens, including methicillin-resistantStaphylococcus aureus(MRSA) and penicillin-resistant pneumococci. In this study, we tested ceftobiprole against various Gram-negative pathogens in a rabbit meningitis model and determined its penetration into the cerebrospinal fluid (CSF). In this animal model, ceftobiprole produced an antibacterial activity similar to that of cefepime against anEscherichia colistrain, aKlebsiella pneumoniaestrain, and a β-lactamase-negativeHaemophilus influenzaestrain. Against a β-lactamase-positiveH. influenzaestrain, ceftobiprole was significantly superior. The penetration of ceftobiprole through inflamed meninges reached about 16% of serum levels compared to about 2% of serum levels through uninflamed meninges.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference22 articles.
1. Ceftobiprole medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788;Anonymous;Drugs R D,2006
2. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model;Arias;J. Antimicrob. Chemother.,2007
3. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia;Azoulay-Dupuis;Antimicrob. Agents Chemother.,2004
4. In vitro antimicrobial activity of silver-processed catheters for neurosurgery;Bayston;J. Antimicrob. Chemother.,2010
5. In vivo verification of in vitro model of antibiotic treatment of device-related infection;Blaser;Antimicrob. Agents Chemother.,1995
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献